These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 15265488)

  • 21. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
    Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
    J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol [(+)-PD 128,907].
    Witkin JM; Dijkstra D; Levant B; Akunne HC; Zapata A; Peters S; Shannon HE; Gasior M
    J Pharmacol Exp Ther; 2004 Mar; 308(3):957-64. PubMed ID: 14711932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP; Markstein R
    Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
    Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
    Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and pharmacological characterization of the human D3 dopamine receptor.
    Freedman SB; Patel S; Marwood R; Emms F; Seabrook GR; Knowles MR; McAllister G
    J Pharmacol Exp Ther; 1994 Jan; 268(1):417-26. PubMed ID: 8301582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
    Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.
    van Vliet LA; Tepper PG; Dijkstra D; Damsma G; Wikström H; Pugsley TA; Akunne HC; Heffner TG; Glase SA; Wise LD
    J Med Chem; 1996 Oct; 39(21):4233-7. PubMed ID: 8863800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
    Gyertyán I; Kiss B; Gál K; Laszlovszky I; Horváth A; Gémesi LI; Sághy K; Pásztor G; Zájer M; Kapás M; Csongor EA; Domány G; Tihanyi K; Szombathelyi Z
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1268-78. PubMed ID: 17170312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
    Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
    Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.
    Elsner J; Boeckler F; Heinemann FW; Hübner H; Gmeiner P
    J Med Chem; 2005 Sep; 48(18):5771-9. PubMed ID: 16134944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}carboxamides.
    Heidler P; Zohrabi-Kalantari V; Calmels T; Capet M; Berrebi-Bertrand I; Schwartz JC; Stark H; Link A
    Bioorg Med Chem; 2005 Mar; 13(6):2009-14. PubMed ID: 15727854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-(4-(4-(2-Halogenophenyl)piperazin-1-yl)butyl) substituted cinnamoyl amide derivatives as dopamine D2 and D3 receptor ligands.
    Saur O; Hackling AE; Perachon S; Schwartz JC; Sokoloff P; Stark H
    Arch Pharm (Weinheim); 2007 Apr; 340(4):178-84. PubMed ID: 17405129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-[2-[4-(4-Chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide: a potent and selective dopamine D4 ligand.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Tortorella V
    J Med Chem; 1998 Nov; 41(24):4903-9. PubMed ID: 9822559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as potent and selective dopamine D3 receptor ligands.
    Mach UR; Hackling AE; Perachon S; Ferry S; Wermuth CG; Schwartz JC; Sokoloff P; Stark H
    Chembiochem; 2004 Apr; 5(4):508-18. PubMed ID: 15185375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
    Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
    Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4-(tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity.
    Berardi F; Ferorelli S; Abate C; Colabufo NA; Contino M; Perrone R; Tortorella V
    J Med Chem; 2004 Apr; 47(9):2308-17. PubMed ID: 15084129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine.
    Kolhatkar RB; Ghorai SK; George C; Reith ME; Dutta AK
    J Med Chem; 2003 May; 46(11):2205-15. PubMed ID: 12747792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: binding activity at D2 and D3 receptors.
    Dutta AK; Fei XS; Reith ME
    Bioorg Med Chem Lett; 2002 Feb; 12(4):619-22. PubMed ID: 11844685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
    Leopoldo M; Lacivita E; Contino M; Colabufo NA; Berardi F; Perrone R
    J Med Chem; 2007 Aug; 50(17):4214-21. PubMed ID: 17649988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.